Print Friendly, PDF & Email


AGE, Advanced Glycation End Products


Catalogue number: AGE102-1.0

Units1 mg
HostRabbit
Application ELISA
IHC not established
Background
This antibody is suitable for the detection of different AGE products in tissues, tissue extracts and body fluids. Long-term incubation of proteins with glucose leads, through Schiff's base and Amadori rearrangement products, to the formation of advanced glycation end products (AGE) which are characterized by fluorescence, brown color and inter- and intra-molecular cross-linking. Recent immunological studies using anti-AGE antibodies demonstrated the presence of AGE in (i) human lens, (ii) renal proximal tubules in patients with diabetic nephropathy and chronic renal failure, (iii) atherosclerotic lesions of arterial walls, (iv) ß2-microglobulin of carpal tunnel amyloid fibril deposits in patients with hemodialysis-related amyloidosis and (v) brain tissues of patients with Alzheimer’s disease. These results suggested the potential role of AGE in normal aging and age-enhanced disease processes. Advanced Glycation End Products (AGE), cross-reactivity BSA and HSA <1%.

Positive Control
human lens, arteriosclerotic plaques

Immunogen
Advanced Glycation End Products /BSA/HSA

Purification Method
Protein A affinity purified IgG in PBS 0.05 M; pH 7.15; 0.85% NaCl; 0.05% sodium azide**

Working Concentration
(liquid conc.) ELISA app. 1 µg/ml, (IHC 5-10 µg/ml)

Concentration
app. 5 mg/ml

Incubation Time
60 min at RT or 18 hr at 2-8°C

Secondary Reagents
We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art. No. AE005).

Product
Protein A affinity purified IgG in PBS 0.05 M; pH 7.15; 0.85% NaCl; 0.05% sodium azide**

Applications
ELISA, IHC not established

Cross Reactivity
Human

Storage
-20°C

References
1. Horiuchi S., Araki N., and Morino Y. (1991) Immunological approach to characterize advanced glycation end products of the Maillard reaction: Evidence for the presence of a common stucture. J. Biol. Chem. 266; 7329-7332. 2. Akari N., Ueno N., Chakrabarti B., Morino Y., and Horiuchi S. (1992) Immunochemical evidence of the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J. Biol. Chem. 267; 10211-10214. 3. Miyata T., Odo O., Inagi R., Iida Y., Araki N., Yamada N., Horiuchi S., Taniguchi N., Maeda, et al. (1993) ß2-Microglobulin modified with advanced glycation end products is a major component of haemodialysis-associated amyloidosis. J. Clin. Invest. 92; 1243-1252. 4. Kume S., Takeya M., Mori T., Araki N., Suzuki H., Horiuchi S., Kodama T., Miyauchi Y., and Takahashi K. (1995) Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta using a novel specific monoclonal antibody. Am J. Pathol. 147; 654-667. 5. Kimura T., Takamatsu J., Ikeda K., Kondo A., Miyakawa T., and Horiuchi S. (1996) Accumulation of advanced glycation end products of the Maillard reactionwith age in human hippocampal neurons. Neurosci. Lett. 208; 53-56.

Caution
These antibodies are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals. ** The preservative sodium azide is known to be poisonous and potentially hazardous to health. It should be handled only by trained staff. Despite of the product's low azide concentration it must be handled with care. Dispose according to regional rules!

Safety Datasheet(s) for this product:

AGE, Advanced Glycation End Products

$1,105.00

SKU: AGE102-1.0 Categories: ,